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Cytomegalovirus Retinitis After Intravitreous Triamcinolone 
Injection in a Patient with Central Retinal Vein Occlusion
Yong‐Sik Park, MD, Suk Ho Byeon, MD
Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea
To report a case of cytomegalovirus (CMV) retinitis after intravitreal injection of triamcinolone acetonide 
(IVTA). A 77‐year‐old woman with macular edema due to central retinal vein occlusion (CRVO) developed 
peripheral retinitis 4 months after IVTA. A diagnostic anterior chamber paracentesis was performed to obtain 
DNA for a polymerase chain reaction (PCR) test for viral retinitis. The PCR test was positive for CMV DNA. 
Other tests for infective uveitis and immune competence were negative. Four months after presentation, 
gancyclovir was intravitreously injected a total of 5 times, and the retinitis resolved completely. CMV retinitis 
is a rare complication of local immunosuppression with IVTA. It can be managed with timely injection of 
intravitreal gancyclovir until recovery from local immunosuppression. 
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Cytomegalovirus (CMV) retinitis remains the most common 
opportunistic ocular infection in immunocompromised 
patients.1 Patients with immunosuppression caused by various 
disease states including acquired immunodeficiency syndrome 
(AIDS) and those with iatrogenic immunosuppression from 
chemotherapy and immune modulators are at risk.1 We 
present a case of CMV retinitis after intravitreal injection of 
triamcinolone acetonide (IVTA) in an immunocompetent 
woman with no other immunocompromising diseases. 
Case Report
A 77‐year‐old woman with a history of hypertension was 
referred to our clinic in September 2006 for a 2‐week history 
of blurred vision in her right eye. She had received an 
intravitreal injection of 4 mg of triamcinolone acetonide in 
her right eye for macular edema due to central retinal vein 
occlusion (CRVO) 4 months previously. Her right eye visual 
acuity was significant for light perception only, and 
ophthalmic examination of the right eye showed many cells 
in the anterior chamber and vitreous, multiple retinal 
hemorrhages and peripheral circumferential retinitis (Fig. 1). 
Serologic tests for infectious uveitis caused by herpes 
zoster virus (HZV), herpes simplex virus (HSV), CMV, 
toxoplasmosis, and syphilis (VDRL), and a test for human 
immunodeficiency virus, were performed. The patient tested 
seronegative for HZV, HSV, CMV, toxoplasma, and HIV, 
and VDRL was non‐reactive. Before starting an oral 
corticosteroid, intravenous injection of acyclovir (2000 
mg/day 4 times a day) was started. Because of a presumed 
diagnosis of acute retinal necrosis or CMV retinitis, 
diagnostic anterior chamber paracentesis was performed, and 
an aqueous humor sample was sent for analysis by 
polymerase chain reaction (PCR) for HZV, HSV, CMV and 
toxoplasmosis. An intravitreous gancyclovir injection (1.7 
mg) was performed immediately after aqueous sampling. The 
aqueous humor PCR sample tested positive only for CMV. 
Five days after the gancyclovir injection, the number of 
inflammatory cells in the anterior chamber decreased to trace 
amounts only, and the vitreous was cleared. Argon laser 
photocoagulation between the area of retinitis and the normal 
retina was performed on the patient’s right eye. Three weeks 
after the first gancyclovir injection, the patient presented with 
an aggravated retinal lesion and chamber reactions in the 
right eye. A second intravitreal gancyclovir (1.7 mg) injection 
was performed. An additional two intravitreal gancyclovir 
(1.7 mg) injections were performed at 2 weeks and 6 weeks 
after the second injection.
Two weeks after the final gancyclovir injection, 
examination of the right eye revealed much improved 
peripheral retinal necrosis with persistent retinitis at the 
inferior periphery. Nine weeks after the last injection (4 
months after the patient’s first visit to our clinic), the retinitis 
was completely resolved. Clear anterior chamber and mild 
sustained vitreous opacity were noted. The patient’s final 
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Fig. 1. Cytomegalovirus (CMV) retinitis 4 months after 
intravitreous injection of triamcinolone acetonide (IVTA). The 
patient initially presented with blurred vision and ghost vessels, 
multiple retinal hemorrhages, and peripheral retinitis.
resultant vision in her right eye was significant for hand 
motion. Her right eye has remained free of retinitis since. 
Discussion
CMV is a ubiquitous human virus and 50‐80% of adults 
in the United States harbor anti‐CMV antibodies.2,3 
Seroprevalence among lower socioeconomic groups, residents 
of developing countries, and homosexual men can exceed 
90%.4 Acquisition of the virus occurs through placental 
transfer, breast feeding, saliva, sexual contact, blood 
transfusions, and organ or bone marrow transplants. Infection 
with CMV leads to life‐long persistence; however, in healthy 
individuals, the virus becomes dormant and remains latent.1 
Reactivation occurs in patients with immature or compromised 
immune systems.1 In iatrogenically immunosuppressed patients 
after organ or bone marrow transplantation, CMV retinitis is 
a rare complication.5,6 Recently, 4 cases of CMV retinitis 
after intravitreal steroid application in immunocompetent 
patients have been reported.7‐9 In comparison with these 
previously published cases, our patient had no medical 
problems such as diabetes mellitus or Behcet’s disease 
that could have impaired her immunity.7‐9 Local 
immunosuppression may be strong enough to allow CMV to 
replicate and lead to retinitis. In our case, symptomatic 
retinitis developed 4 months after the injection of intravitreal 
triamcinolone. The retinitis was completely resolved 8 
months after IVTA. The local immunosuppressive effect of 
IVTA is thought to persist up to 8 months after injection. The 
poor visual outcome in this case was thought to be mainly 
due to the patient’s baseline disease. Timely treatment with 
intravitreal injection of gancyclovir until local immune 
recovery may be effective for local immunosuppression‐
induced CMV retinitis.
Ophthalmologists using intravitreal triamcinolone injections 
should be aware of the potential risk of subsequent CMV 
retinitis. Early diagnosis and treatment with intravitreal 
injections of gancyclovir until recovery is obtained may 
prevent further complications.
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